Hear from expert faculty as they present their insights on some of the most clinically relevant new data presented at AIDS 2022, including prevention strategies, oral therapies, long-acting therapies, and COVID-19 in PWH.
Hear from expert faculty members as they present nursing insights on some of the most clinically relevant new data presented at CROI 2022, including prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.
Listen to expert faculty as they discuss inequities in PrEP uptake in key populations, structural barriers to PrEP adoption, and solutions for expanding PrEP use.
Hear from expert faculty members as they present some of the most clinically relevant new data presented at CROI 2022 and discuss how they will incorporate the data on prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure strategies into their own practices.
Hear from expert faculty members as they present some of the most clinically relevant new data presented at AIDS 2022 and discuss how they will incorporate the data on prevention strategies, oral therapies, long-acting therapies, cure strategies, COVID-19, and monkeypox into their own practices.
Listen to Timothy J. Wilkin, MD, MPH, discuss barriers to PrEP uptake in adolescents.
Listen to Timothy J. Wilkin, MD, MPH, discuss barriers to PrEP uptake in the context of race.
Listen to Timothy J. Wilkin, MD, MPH, discuss barriers to PrEP uptake for cisgender women.
Listen to Timothy J. Wilkin, MD, MPH, discuss barriers to PrEP uptake for transgender women.
Listen to Timothy J. Wilkin, MD, MPH, discuss barriers to PrEP uptake for people who inject drugs.
Listen to Timothy J. Wilkin, MD, MPH, discuss solutions for expanding PrEP uptake.
Listen to Paul E. Sax, MD, discuss what’s new in long-acting injectables for HIV treatment.
Listen to Paul E. Sax, MD, discuss the latest recommendations and options for HIV pre-exposure prophylaxis.
Listen to Roger Bedimo, MD, MS, FACP, discuss key considerations for switching ART in virologically suppressed patients who are pregnant or trying to conceive.
Listen to Timothy J. Wilkin, MD, MPH, provide a case-based overview of switching antiretroviral therapy in a person with viral suppression on their current regimen who has a history of virologic failure with drug-resistance mutations.
Learn about ART selection in treatment-naive PWH based on the latest guideline recommendations through case-based discussions by Princy N. Kumar, MD, FIDSA, MACP.
Listen to this patient case from Princy N. Kumar MD, FIDSA, MACP, as she shares the latest data on weight gain after ART initiation.
Read expert faculty members’ summaries of key HIV studies from CROI 2022, including results from studies of prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.
Read expert faculty members’ summaries of cutting-edge concepts in HIV care, including the latest for long-acting therapies and prevention.
Read expert faculty members’ summaries of key HIV studies from CROI 2022, including results from studies of prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.
Read expert faculty summaries on the latest data in first-line ART therapy in diverse patients to assist with individualized ART selection.
Read expert faculty members’ summaries of barriers and solutions to PrEP uptake in key populations including, adolescents, Black and Hispanic/Latinx people, cisgender women, transgender women, and people who inject drugs.
Read expert faculty members’ summaries of state-of-the-art switch strategies in virologically suppressed patients, including switching ART in the setting of resistance, considerations for long acting injectables, and switching ART prior to or during pregnancy.
Read expert faculty members’ summaries of barriers and solutions to PrEP uptake in key populations including, adolescents, Black and Hispanic/Latinx people, cisgender women, transgender women, and people who inject drugs.
Read expert faculty members’ summaries of barriers and solutions to PrEP uptake in key populations including, adolescents, Black and Hispanic/Latinx people, cisgender women, transgender women, and people who inject drugs.
Read expert faculty members’ summaries of cutting-edge concepts in HIV care, including the latest for long-acting therapies and prevention.
Download slides to review expert insights into strategies for overcoming virologic failure in heavily treatment–experienced patients and selecting optimized switch regimens for virologically suppressed patients with underlying resistance and significant potential drug–drug interactions.
Read expert faculty members’ summaries of key HIV studies from AIDS 2022, including results from studies of prevention strategies, oral therapies, long-acting therapies, cure, COVID-19 in PWH, and Monkeypox.
Read expert faculty members’ summaries of key HIV studies from AIDS 2022, including results from studies of prevention strategies, oral therapies, long-acting therapies, and COVID-19 in PWH.
Read expert nursing faculty members’ summaries of cutting-edge concepts in HIV care, including the latest for long-acting therapies and prevention.
Download slides to review expert pharmacist insights into strategies for overcoming virologic failure in heavily treatment–experienced patients and selecting optimized switch regimens for virologically suppressed patients with underlying resistance and significant potential drug–drug interactions.
Download slides to review expert nurse insights into strategies for overcoming virologic failure in heavily treatment–experienced patients and selecting optimized switch regimens for virologically suppressed patients with underlying resistance and significant potential drug–drug interactions.
Major inequities in PrEP uptake, adherence, and persistence have been seen in Black and Hispanic/Latinx people, cisgender women, transgender women, adolescents, and people who inject drugs. Here’s how we can address them.
We now have long-acting injectable options for both the treatment and prevention of HIV, with more to learn as we incorporate this exciting new paradigm. Here are my thoughts on key differences among available HIV prevention medications and the potential role of individual pharmacokinetic variability in the efficacy of long-acting options for prevention and treatment.
Finding an appropriate and effective therapeutic regimen for treatment-experienced people with HIV can be challenging. Read my summary of the current options available for managing these complex cases.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.